Alon Harris

Alon Harris, MS, PhD

About Me

Dr. Alon Harris is Vice Chair of International Research and Academic Affairs at Mount Sinai Hospital, Director of Ophthalmic Vascular Diagnostic & Research Program, and Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai.  

An internationally recognized clinical research scientist, Professor Harris focuses on glaucoma risk factor assessment, monitoring techniques for structural and functional glaucoma progression, ocular perfusion assessment, mathematical modeling and artificial intelligence, branded and generic glaucoma medications, novel imaging methodologies and population-based studies. In addition, Professor Harris has made significant contributions involving vascular deficits in the fields of diabetic retinopathy, age-related macular degeneration, non-arteritic ischemic optic neuropathy, and brain physiology.

Prior to joining Mount Sinai, Professor Harris served as the Letzter endowed chair of Ophthalmology and Director of Clinical Research for the Department of Ophthalmology (2010-2018) and additionally served on numerous leadership councils, both departmentally and university-wide, chairing the Diversity Committee for the Department of Ophthalmology at Indiana University School of Medicine, Indianapolis, Indiana.   At Indiana University he founded and served as Director for one of the world’s leading centers for ocular blood flow and its implications to glaucoma: The Glaucoma Research and Diagnostic Center.

Professor Harris has published over 358 peer-reviewed journal articles, 22 books and 66 book chapters. He has received over 6 million dollars in research funds from prestigious institutions including the National Institutes of Health (NIH), National Science Foundation (NSF), American Diabetes Association (ADA), and the National Eye Institute (NEI) in the United States.    

In addition to his academic pursuits Professor Harris is a highly sought-after expert consultant in both regulatory affairs and start-up considerations of biotech and pharmaceutical industries. He is the founder of AdOM, an ophthalmic medical imaging company for dry eye and he serves on the board of several life sciences and startup companies. He has served as Chairman of the Board for XLVision and served as a senior consultant for Oxymap, Nano Retina, Science Based Health, and Isarna Therapeutics among others.

Professor Harris holds two issued patents related to ocular blood flow: 1) Novel Treatment of Macular Edema; and 2) Method to Increase Retinal and Optic Nerve Head Blood Flow; and has other patents pending related to mathematical modeling and artificial intelligence in ophthalmic health and disease.

Language
English
Position
PROFESSOR | Ophthalmology